OOIR: Observatory of International Research

Papers

(The H4-Index of Antiviral Research is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Broad antibody and T cell responses to Ebola, Sudan, and Bundibugyo ebolaviruses using mono- and multi-valent adjuvanted glycoprotein vaccines	333
Host-targeting antivirals for chronic viral infections of the liver	94
Serum O-glycosylated HBsAg levels correlate with HBV RNA in HBeAg positive CHB patients during antiviral therapy	78
Seeking innovative concepts in development of antiviral drug combinations	70
Prevention of post COVID-19 condition by early treatment with ensitrelvir in the phase 3 SCORPIO-SR trial	52
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2	52
Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern	51
Novel inhibitors of HSV-1 protease effective in vitro and in vivo	50
Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment	50
Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants	50
Mouse models of Zika virus transplacental transmission	50
Increased ILT2 expression contributes to dysfunction of CD56dimCD16+NK cells in chronic hepatitis B virus infection	46
A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency	39
Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus	39
A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge	38
Editorial Board	37
Identification of a macrocyclic compound targeting the lassa virus polymerase	36
Characterization and noncovalent inhibition of the K63-deubiquitinase activity of SARS-cov-2 PLpro	35
RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination	34
Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod and its mechanism of action	33
Editorial Board	33
Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV.	30
Evaluation of panel of neutralising murine monoclonal antibodies and a humanised bispecific antibody against influenza A(H1N1)pdm09 virus infection in a mouse model	29
Validation of nuclear receptor RORγ isoform 1 as a novel host-directed antiviral target based on the modulation of cholesterol levels	29
A safe replication-defective Zika virus vaccine protects mice from viral infection and vertical transmission	29

Caffeic acid phenethyl ester: an effective antiviral agent against porcine reproductive and Respiratory Syndrome Virus	29
Investigating the virulence of coxsackievirus B6 strains and antiviral treatments in a neonatal murine model	29
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies	28
Cellular electrical impedance to profile SARS-CoV-2 fusion inhibitors and to assess the fusogenic potential of spike mutants	28
Editorial Board	28
Editorial Board	28